GSK rolls out new DTC ads for Lovaza

Share this article:
GSK rolls out new DTC ads for Lovaza
GSK rolls out new DTC ads for Lovaza

GlaxoSmithKline launched new TV spots last week for Lovaza, a prescription omega-3 fish oil capsule indicated for the lowering of very high triglyceride levels.

TV spots, as well as the consumer print and online ads that debuted in January, emphasize the drug's natural ingredient: "Lovaza — the prescription that starts in the sea." On television, a white-coated physician handles beakers in a lab surrounded by a gigantic wall-sized aquarium.

Bernadette King, a GSK spokesperson, said the campaign targets "people at higher risk," such as Type 2 diabetics, people with high blood pressure, high cholesterol, and the overweight. "There's a big potential to educate consumers on high triglycerides," she said.

King hastened to add that Lovaza is not indicated for the prevention of cardiovascular events. The campaign is geared toward reducing high triglyceride levels and building awareness around the disease, she said. "We hope it will promote patient-doctor dialogues, which should be the focus of any DTC campaign," said King

McCann HumanCare created the DTC work for Lovaza, and imc2 worked on digital and online elements, said King.

Online content at Lovaza.com includes patient testimonials and a "Put Lovaza to the Test" game for visitors. A coupon on the website offers $20 off 12 refills of the drug, which costs around $160 for a month supply, according to Consumer Reports.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...